Abstract
Clinical signs of upper motor neuron (UMN) involvement are an important component in supporting the diagnosis of amyotrophic lateral sclerosis (ALS), but are often not easily appreciated in a limb that is concurrently affected by muscle wasting and lower motor neuron degeneration, particularly in the early symptomatic stages of ALS. Whilst recent criteria have been proposed to facilitate improved detection of lower motor neuron impairment through electrophysiological features that have improved diagnostic sensitivity, assessment of upper motor neuron involvement remains essentially clinical. As a result, there is often a significant diagnostic delay that in turn may impact institution of disease-modifying therapy and access to other optimal patient management. Biomarkers of pathological UMN involvement are also required to ensure patients with suspected ALS have timely access to appropriate therapeutic trials. The present review provides an analysis of current and recently developed assessment techniques, including novel imaging and electrophysiological approaches used to study corticomotoneuronal pathology in ALS.
| Original language | English |
|---|---|
| Journal | Clinical Neurophysiology |
| Volume | 127 |
| Issue number | 7 |
| Pages (from-to) | 2643-2660 |
| Number of pages | 18 |
| ISSN | 1388-2457 |
| DOIs | |
| Publication status | Published - 01.07.2016 |
| Externally published | Yes |
Funding
WH was supported by the University of Sydney post-doctoral research fellowship. This work was supported by funding to Forefront, a collaborative research group dedicated to the study of motor neuron disease, from the National Health and Medical Research Council of Australia program grant ( #1037746 ). MRT is funded by the Medical Research Council and Motor Neuron Disease Association Lady Edith Wolfson Fellowship ( MR/K01014X/1 ).
Research Areas and Centers
- Centers: Center for Neuromuscular Diseases